Research progresses of the PARP inhibitors for the treatment of cancer.
- Author:
Yu-Jun HE
1
;
Rui-Huan LIU
;
Cheng-Qing NING
;
Nie-Fang YU
Author Information
1. School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.
- Publication Type:Journal Article
- MeSH:
Animals;
Antineoplastic Agents;
therapeutic use;
Benzimidazoles;
therapeutic use;
Breast Neoplasms;
drug therapy;
genetics;
DNA Repair;
Drug Therapy, Combination;
Enzyme Inhibitors;
therapeutic use;
Female;
Humans;
Indoles;
therapeutic use;
Melanoma;
drug therapy;
Mutation;
Ovarian Neoplasms;
drug therapy;
genetics;
Phthalazines;
therapeutic use;
Piperazines;
therapeutic use;
Poly(ADP-ribose) Polymerase Inhibitors
- From:
Acta Pharmaceutica Sinica
2013;48(5):655-660
- CountryChina
- Language:Chinese
-
Abstract:
The poly(ADP-ribose) polymerases (PARPs) is an important group of enzymes in DNA repair pathways, especially the base excision repair (BER) for DNA single-strand breaks (SSBs) repair. Inhibition of PARP in DNA repair-defective tumors (like those with BRAC1/2 mutations) can lead to cell death and genomic instability, what is so called "synthetic lethality". Currently, PARP inhibitors combined with cytotoxic chemotherapeutic agents in the treatment of BRCA-1/2 deficient cancers are in the clinical development. In this review, we will be focused on the development of combination application of PARP inhibitors with other anticancer agents in clinical trials.
